Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Ueno M, Takeda H, Takai A, Morimura H, et al. Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study. J Gastroenterol 2024 Oct 21. doi: 10.1007/s00535-024-02159.
PMID: 39432084


Privacy Policy